Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors

被引:51
|
作者
Tian, You-yong
Tang, Cui-Ju
Wang, Jia-ning
Feng, Yuan
Chen, Xiao-wu
Wang, Lan
Qiao, Xian
Sun, Sheng-gang [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Union Hosp, Dept Neurol, Wuhan 430022, Peoples R China
[2] Nanjing Med Univ, Affiliated Nanjing Hosp 1, Dept Neurol, Nanjing 210006, Peoples R China
[3] Nanjing Med Univ, Affiliated Nanjing Hosp 1, Dept Oncol, Nanjing 210006, Peoples R China
[4] Affiliated Peoples Hosp, Yunyang Med Coll, Inst Clin Med, Shiyan 442000, Peoples R China
关键词
adeno-associated virus; endothelial growth factor; neurodegeneration; Parkinson's disease; ENDOTHELIAL GROWTH-FACTOR; DOPAMINERGIC-NEURONS; MESENCEPHALIC CELLS; VIRUS VECTOR; IN-VITRO; NEUROPROTECTION; TRANSDUCTION; DEGENERATION; EXPRESSION; BRAIN;
D O I
10.1016/j.neulet.2007.05.033
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vascular endothelial growth factor (VEGF) is a specific angiogenic peptide, which has been identified to play a critical role in neurodegeneration, and has beneficial effects on neurons. In this study, we investigated whether neurodegeneration in a rat model of Parkinson disease could be prevented by VEGF gene transfer mediated by adeno-associated virus (AAV) vectors. Our results demonstrated that a single injection of a VEGF-expressing AAV vector into striatum improved the rotational behavior of rat Parkinson disease models, and promoted the survival of dopaminergic neurons and fibers. Meanwhile. AAV-VEGF injection significantly increased the reactive astrocytes and the levels of glial cell line-derived neurotrophic factor in striatum, but did not induce extra angiogenesis and remarkable disorder of blood-brain barrier. We thus conclude that intrastriatal delivery of VEGF gene mediated by AAV has favorable effects on the dopaminergic neurons in a rat Parkinson disease model. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:239 / 244
页数:6
相关论文
共 50 条
  • [1] Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors
    Muramatsu, S
    Tsukada, H
    Nakano, I
    Ozawa, K
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (05) : 663 - 671
  • [2] Adeno-associated viral vectors for Parkinson's disease
    Muramatsu, S
    Wang, LJ
    Ikeguchi, K
    Fujimoto, K
    Nakano, I
    Okada, T
    Mizukami, H
    Hanazono, Y
    Kume, A
    Nakano, I
    Ozawa, K
    VIRAL VECTORS FOR TREATING DISEASES OF THE NERVOUS SYSTEM, 2003, 55 : 205 - 222
  • [3] Adeno-associated viral vectors for retinal gene transfer
    Surace, EM
    Auricchio, A
    PROGRESS IN RETINAL AND EYE RESEARCH, 2003, 22 (06) : 705 - 719
  • [4] In Vivo Gene Transfer to the Pancreas Using Adeno-Associated Viral Vectors
    Jimenez, V.
    Ayuso, E.
    Agudo, J.
    Salavert, A.
    Munoz, S.
    Moya, M.
    Leon, X.
    Ruberte, J.
    Bosch, F.
    HUMAN GENE THERAPY, 2009, 20 (09) : 1041 - 1042
  • [5] Adeno-associated viral vectors for clinical gene transfer studies
    Snyder, RO
    Francis, J
    CURRENT GENE THERAPY, 2005, 5 (03) : 311 - 321
  • [6] Tailoring adeno-associated viral vectors for gene transfer and gene therapy
    Buening, Hildegard
    HUMAN GENE THERAPY, 2011, 22 (06) : A3 - A3
  • [7] Adeno-Associated Viral Vectors for Gene Therapy
    Dalkara, Deniz
    OPHTHALMOLOGICA, 2014, 232 : 8 - 9
  • [8] Adeno-associated viral vectors for gene therapy
    Summerford, C
    Samulski, RJ
    BIOGENIC AMINES, 1998, 14 (05) : 451 - 475
  • [9] The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors
    Schuettrumpf, J
    Zou, JX
    Zhang, Y
    Schlachterman, A
    Liu, YL
    Edmonson, S
    Xiao, WD
    Arruda, VR
    MOLECULAR THERAPY, 2006, 13 (01) : 88 - 97
  • [10] Gene delivery to the eye using adeno-associated viral vectors
    Martin, KRG
    Klein, RL
    Quigley, HA
    METHODS, 2002, 28 (02) : 267 - 275